{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:38:29Z","timestamp":1792183109785,"version":"4.4.0"},"reference-count":483,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.chest.2018.07.040","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T15:44:25Z","timestamp":1534952665000},"page":"1121-1201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":849,"title":["Antithrombotic Therapy for Atrial Fibrillation"],"prefix":"10.1016","volume":"154","author":[{"given":"Gregory Y.H.","family":"Lip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitava","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chern en","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiz","family":"Fargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre A.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T.","family":"Ruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mintu","family":"Turakhia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Werring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Moores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.chest.2018.07.040_bib1","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1160\/TH16-11-0876","article-title":"Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making","volume":"117","author":"Lip","year":"2017","journal-title":"Thromb Haemost"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: an integrated approach to improve AF management","volume":"14","author":"Lip","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"suppl 2","key":"10.1016\/j.chest.2018.07.040_bib3","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"issue":"23","key":"10.1016\/j.chest.2018.07.040_bib4","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.jacc.2016.09.944","article-title":"Causes of death in anticoagulated patients with atrial fibrillation","volume":"68","author":"Gomez-Outes","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.chest.2018.07.040_bib5","unstructured":"Higgins J, Altman D, Sterne J, (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.\u00a02011."},{"key":"10.1016\/j.chest.2018.07.040_bib6","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.13105\/wjma.v3.i3.142","article-title":"Development of the Documentation and Appraisal Review Tool for systematic reviews","volume":"3","author":"Diekemper","year":"2015","journal-title":"World J Meta-Anal"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib8","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/europace\/euu129","article-title":"Incidence and predictors of atrial fibrillation and its impact on long-term survival in patients with supraventricular arrhythmias","volume":"16","author":"Ozcan","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.chest.2018.07.040_bib9","unstructured":"Higgins J, Altman D, Sterne J, (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. www.cochrane-handbook.org.\u00a02011."},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib11","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.chest.2016.04.018","article-title":"Making the GRADE: CHEST updates its methodology","volume":"153","author":"Diekemper","year":"2018","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.chest.2018.07.040_bib12","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib13","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1378\/chest.14-0824","article-title":"Methodologies for the development of CHEST guidelines and expert panel reports","volume":"146","author":"Lewis","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.chest.2018.07.040_bib14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/bmj.a744","article-title":"Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive","volume":"337","author":"Jaeschke","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.chest.2018.07.040_bib15","doi-asserted-by":"crossref","first-page":"16016","DOI":"10.1038\/nrdp.2016.16","article-title":"Atrial fibrillation","volume":"2","author":"Lip","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib16","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1378\/chest.11-2888","article-title":"The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe","volume":"142","author":"Lip","year":"2012","journal-title":"Chest"},{"issue":"10046","key":"10.1016\/j.chest.2018.07.040_bib17","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0140-6736(16)31257-0","article-title":"Stroke prevention in atrial fibrillation","volume":"388","author":"Freedman","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib18","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1160\/TH16-11-0825","article-title":"Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants","volume":"117","author":"Allan","year":"2017","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib19","first-page":"CD009586","article-title":"Systematic screening for the detection of atrial fibrillation","author":"Moran","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib20","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.amjcard.2011.08.046","article-title":"Insights into management of atrial fibrillation in Asia Pacific gained from baseline data from REgistry on cardiac rhythm disORDers (RecordAF-Asia Pacific [AP]) registry","volume":"109","author":"Amerena","year":"2012","journal-title":"Am J Cardiol"},{"issue":"15","key":"10.1016\/j.chest.2018.07.040_bib21","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1161\/CIRCULATIONAHA.113.005451","article-title":"Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry","volume":"129","author":"Oldgren","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.chest.2018.07.040_bib22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ijcard.2016.08.236","article-title":"Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry","volume":"223","author":"Oh","year":"2016","journal-title":"Int J Cardiol"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib23","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1253\/circj.CJ-11-0427","article-title":"Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan. Subanalysis of the J-RHYTHM Registry","volume":"75","year":"2011","journal-title":"Circ J"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib24","first-page":"260","article-title":"Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry","volume":"61","author":"Akao","year":"2013","journal-title":"J\u00a0Cardiol"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib25","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ijcard.2012.10.052","article-title":"Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation","volume":"168","author":"Guo","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.chest.2018.07.040_bib26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ijcard.2016.06.113","article-title":"Uptake of evidence-based statin therapy among atrial fibrillation patients in China: a report from the CAFR (Chinese Atrial Fibrillation Registry) Study","volume":"220","author":"Xia","year":"2016","journal-title":"Int J Cardiol"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib27","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/europace\/euw073","article-title":"Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort","volume":"18","author":"Huisman","year":"2016","journal-title":"Europace"},{"issue":"16","key":"10.1016\/j.chest.2018.07.040_bib28","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.jacc.2014.06.1203","article-title":"Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation","volume":"64","author":"Chao","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib29","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.hrthm.2014.04.021","article-title":"Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong","volume":"11","author":"Siu","year":"2014","journal-title":"Heart Rhythm"},{"issue":"22","key":"10.1016\/j.chest.2018.07.040_bib30","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","article-title":"Atrial fibrillation management: a prospective survey in ESC member countries","volume":"26","author":"Nieuwlaat","year":"2005","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.amjcard.2009.10.012","article-title":"The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation","volume":"105","author":"Le Heuzey","year":"2010","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib32","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ahj.2012.12.019","article-title":"Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry","volume":"165","author":"Steinberg","year":"2013","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib33","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/europace\/eut373","article-title":"A\u00a0prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry","volume":"16","author":"Lip","year":"2014","journal-title":"Europace"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/eut263","article-title":"Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events\u2014European Registry in Atrial Fibrillation (PREFER in AF)","volume":"16","author":"Kirchhof","year":"2014","journal-title":"Europace"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib35","first-page":"204","article-title":"Oral anticoagulation for stroke prevention in Canadian practice: Stroke Prevention and Rhythm Interventions in Atrial Fibrillation (SPRINT-AF) Registry","volume":"32","author":"Ha","year":"2016","journal-title":"Can J Cardiol"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib36","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/CIRCOUTCOMES.110.959700","article-title":"Gulf Survey of Atrial Fibrillation Events (Gulf SAFE): design and baseline characteristics of patients with atrial fibrillation in the Arab Middle East","volume":"4","author":"Zubaid","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib37","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jfma.2016.10.005","article-title":"2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation","volume":"115","author":"Chiang","year":"2016","journal-title":"J\u00a0Formosan Medical Assoc"},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib38","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3121\/cmr.2009.851","article-title":"Atrial flutter versus atrial fibrillation in a general population: differences in comorbidities associated with their respective onset","volume":"8","author":"Mareedu","year":"2010","journal-title":"Clin Med Res"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib40","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/ijcp.12281","article-title":"Lone atrial fibrillation\u2014an overview","volume":"68","author":"Potpara","year":"2014","journal-title":"Int J Clin Pract"},{"issue":"7","key":"10.1016\/j.chest.2018.07.040_bib41","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1016\/S0735-1097(00)00982-7","article-title":"Incidence and predictors of atrial flutter in the general population","volume":"36","author":"Granada","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib42","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1253\/circj.CJ-12-1036","article-title":"Stroke and thromboembolism in atrial fibrillation","volume":"76","author":"Pisters","year":"2012","journal-title":"Circ J"},{"issue":"20","key":"10.1016\/j.chest.2018.07.040_bib43","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/eurheartj\/ehw007","article-title":"The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis","volume":"37","author":"Ganesan","year":"2016","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib44","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1445-5994.2009.01991.x","article-title":"Atrial fibrillation and the risk of death in patients with heart failure: a literature-based meta-analysis","volume":"40","author":"Wasywich","year":"2010","journal-title":"Intern Med J"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib45","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jama.2015.10725","article-title":"Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation","volume":"314","author":"Melgaard","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib46","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrcardio.2015.191","article-title":"Comorbidity of atrial fibrillation and heart failure","volume":"13","author":"Ling","year":"2016","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"10.1016\/j.chest.2018.07.040_bib47","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1177\/2047487314544045","article-title":"Performance of the CHARGE-AF risk model for incident atrial fibrillation in the EPIC Norfolk cohort","volume":"22","author":"Pfister","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.chest.2018.07.040_bib48","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ijcard.2015.10.220","article-title":"Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: a systematic review and meta-analysis of death and adverse outcomes","volume":"203","author":"Kotecha","year":"2016","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib49","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1161\/STROKEAHA.114.006881","article-title":"Risk of thromboembolic events in atrial fibrillation with chronic kidney disease","volume":"46","author":"Zeng","year":"2015","journal-title":"Stroke"},{"issue":"7","key":"10.1016\/j.chest.2018.07.040_bib50","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2018.07.040_bib51","doi-asserted-by":"crossref","first-page":"i4482","DOI":"10.1136\/bmj.i4482","article-title":"Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis","volume":"354","author":"Odutayo","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.chest.2018.07.040_bib52","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijcard.2016.11.303","article-title":"Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: a systematic review and network meta-analysis","volume":"231","author":"Ando","year":"2017","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib53","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1378\/chest.15-1719","article-title":"Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies","volume":"149","author":"Dahal","year":"2016","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5603\/CJ.a2013.0116","article-title":"Systematic review and meta-analysis of chronic kidney disease as predictor of atrial fibrillation recurrence following catheter ablation","volume":"21","author":"Li","year":"2014","journal-title":"Cardiol J"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib55","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.hrthm.2014.09.058","article-title":"Cryptogenic stroke: is silent atrial fibrillation the culprit?","volume":"12","author":"Glotzer","year":"2015","journal-title":"Heart Rhythm"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib56","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1747493016669885","article-title":"Cardiac monitoring for detection of atrial fibrillation after TIA: a systematic review and meta-analysis","volume":"12","author":"Korompoki","year":"2017","journal-title":"Int J Stroke"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib57","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.echo.2013.05.010","article-title":"The role of echocardiography in thromboembolic risk assessment of patients with nonvalvular atrial fibrillation","volume":"26","author":"Providencia","year":"2013","journal-title":"J\u00a0Am Soc Echocardiogr"},{"issue":"7","key":"10.1016\/j.chest.2018.07.040_bib58","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0735-1097(98)00146-6","article-title":"Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators","volume":"31","author":"Zabalgoitia","year":"1998","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib59","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0735-1097(94)90025-6","article-title":"Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation","volume":"24","author":"Leung","year":"1994","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib60","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrcardio.2016.106","article-title":"Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy","volume":"13","author":"Calenda","year":"2016","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib61","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1161\/CIRCULATIONAHA.116.024057","article-title":"Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation","volume":"135","author":"Quinn","year":"2017","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib62","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1161\/CIRCULATIONAHA.116.025944","article-title":"Adding rigor to stroke rate investigations in patients with atrial fibrillation","volume":"135","author":"Nielsen","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.chest.2018.07.040_bib63","doi-asserted-by":"crossref","first-page":"27410","DOI":"10.1038\/srep27410","article-title":"Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: a nationwide cohort study","volume":"6","author":"Nielsen","year":"2016","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib64","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2015.07.026","article-title":"Age threshold for increased stroke risk among patients with atrial fibrillation: a nationwide cohort study from Taiwan","volume":"66","author":"Chao","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib65","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/STROKEAHA.116.013880","article-title":"Validation of a modified CHA2DS2-VASc score for stroke risk stratification in Asian patients with atrial fibrillation: a nationwide cohort study","volume":"47","author":"Chao","year":"2016","journal-title":"Stroke"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib66","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1161\/CIRCULATIONAHA.117.029081","article-title":"Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc?","volume":"137","author":"Nielsen","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib67","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacc.2017.10.085","article-title":"Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation","volume":"71","author":"Chao","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9609","key":"10.1016\/j.chest.2018.07.040_bib68","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(08)60168-3","article-title":"Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial","volume":"371","author":"Bousser","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib69","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A\u00a0New risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study","volume":"58","author":"Fang","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib70","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.clinthera.2013.08.013","article-title":"Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population","volume":"35","author":"Deitelzweig","year":"2013","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib71","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib72","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib73","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib74","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib75","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation\u2014the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"issue":"22","key":"10.1016\/j.chest.2018.07.040_bib76","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib77","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1055\/s-0038-1636534","article-title":"Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and Delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors","volume":"118","author":"Chao","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.chest.2018.07.040_bib78","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2017.11.025","article-title":"Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study","volume":"254","author":"Chao","year":"2018","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib79","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.amjmed.2017.09.009","article-title":"Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation","volume":"131","author":"Guo","year":"2018","journal-title":"Am J Med"},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib80","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1160\/TH17-10-0710","article-title":"Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED Score. The AMADEUS Trial","volume":"117","author":"Esteve-Pastor","year":"2017","journal-title":"Thromb Haemost"},{"issue":"suppl 2","key":"10.1016\/j.chest.2018.07.040_bib81","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib82","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-141-10-200411160-00005","article-title":"Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation","volume":"141","author":"Fang","year":"2004","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib83","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1056\/NEJM199608223350802","article-title":"An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation","volume":"335","author":"Hylek","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.chest.2018.07.040_bib84","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1001\/archinternmed.2009.419","article-title":"The international normalized ratio range of 2.0 to 3.0 remains appropriate for atrial fibrillation","volume":"169","author":"Singer","year":"2009","journal-title":"Arch Intern Med"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib85","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.hrthm.2008.07.014","article-title":"Epidemiology and outcomes in patients with atrial fibrillation in the United States","volume":"5","author":"Walker","year":"2008","journal-title":"Heart Rhythm"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib86","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.thromres.2013.10.024","article-title":"Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes","volume":"132","author":"Witt","year":"2013","journal-title":"Thrombosis Res"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib87","doi-asserted-by":"crossref","first-page":"e74037","DOI":"10.1371\/journal.pone.0074037","article-title":"Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial","volume":"8","author":"Clarkesmith","year":"2013","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib88","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0029-1240016","article-title":"Management strategies for optimal control of anticoagulation in patients with atrial fibrillation","volume":"35","author":"Levi","year":"2009","journal-title":"Semin Thromb Hemost"},{"issue":"17","key":"10.1016\/j.chest.2018.07.040_bib89","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJMoa1002617","article-title":"Effect of home testing of international normalized ratio on clinical events","volume":"363","author":"Matchar","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib90","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1378\/chest.129.5.1155","article-title":"Effect of study setting on anticoagulation control: a systematic review and metaregression","volume":"129","author":"van Walraven","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.chest.2018.07.040_bib91","first-page":"CD003839","article-title":"Self-monitoring and self-management of oral anticoagulation","volume":"7","author":"Heneghan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"45","key":"10.1016\/j.chest.2018.07.040_bib92","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib93","first-page":"93","article-title":"Bridging anticoagulation in\u00a0patients with atrial fibrillation","volume":"374","author":"Douketis","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib94","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMoa1501035","article-title":"Perioperative bridging anticoagulation in patients with atrial fibrillation","volume":"373","author":"Douketis","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.chest.2018.07.040_bib95","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/archinte.159.7.677","article-title":"Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls","volume":"159","author":"Man-Son-Hing","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.chest.2018.07.040_bib96","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijcard.2018.01.097","article-title":"Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants","volume":"264","author":"Pastori","year":"2018","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib97","article-title":"Liver cirrhosis in patients with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention?","volume":"6","author":"Kuo","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib98","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A\u00a0novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib99","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am Heart J"},{"issue":"10035","key":"10.1016\/j.chest.2018.07.040_bib100","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study","volume":"387","author":"Hijazi","year":"2016","journal-title":"Lancet"},{"issue":"46","key":"10.1016\/j.chest.2018.07.040_bib101","first-page":"3258","article-title":"The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation","volume":"36","author":"O'Brien","year":"2015","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib102","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1378\/chest.130.5.1390","article-title":"Development of a contemporary bleeding risk model for elderly warfarin recipients","volume":"130","author":"Shireman","year":"2006","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.chest.2018.07.040_bib103","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.amjcard.2017.06.058","article-title":"Bleeding risk scores in atrial fibrillation and venous thromboembolism","volume":"120","author":"Zulkifly","year":"2017","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib104","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1160\/TH13-07-0552","article-title":"Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial","volume":"110","author":"Apostolakis","year":"2013","journal-title":"Thromb Haemost"},{"issue":"23","key":"10.1016\/j.chest.2018.07.040_bib105","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2013.08.1623","article-title":"The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation","volume":"62","author":"Roldan","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib106","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/clc.22435","article-title":"The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis","volume":"38","author":"Zhu","year":"2015","journal-title":"Clin Cardiol"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib107","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1378\/chest.13-1635","article-title":"Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation: the AMADEUS Study","volume":"144","author":"Lip","year":"2013","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib108","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1160\/TH13-12-1033","article-title":"Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project","volume":"111","author":"Banerjee","year":"2014","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib109","doi-asserted-by":"crossref","first-page":"672","DOI":"10.4244\/EIJV8I6A105","article-title":"Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score","volume":"8","author":"Smith","year":"2012","journal-title":"EuroIntervention"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib110","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1161\/CIRCRESAHA.116.309955","article-title":"Novel Risk Markers and Risk Assessments for Cardiovascular Disease","volume":"120","author":"Thomas","year":"2017","journal-title":"Circ Res"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib111","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.91455","article-title":"GDF15 is elevated in mice following retinal ganglion cell death and in glaucoma patients","volume":"2","author":"Ban","year":"2017","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.chest.2018.07.040_bib112","article-title":"Long-term stroke risk prediction in patients with atrial fibrillation: comparison of the ABC-Stroke and CHA2DS2-VASc scores","volume":"6","author":"Rivera-Caravaca","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib113","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1160\/TH17-07-0478","article-title":"Long-term bleeding risk prediction in \u2018real world\u2019 patients with atrial fibrillation: comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project","volume":"117","author":"Esteve-Pastor","year":"2017","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib114","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/jth.13386","article-title":"Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores","volume":"14","author":"Lip","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib115","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10840-014-9930-y","article-title":"Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"40","author":"Caldeira","year":"2014","journal-title":"J\u00a0Interv Card Electrophysiol"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib116","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jacc.2012.10.010","article-title":"Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in nonwarfarin anticoagulated atrial fibrillation patients","volume":"61","author":"Apostolakis","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib117","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacc.2012.06.019","volume":"60","author":"Apostolakis","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib118","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.amjmed.2015.10.001","article-title":"Evaluation of the HAS-BLED, ATRIA, and ORBIT bleeding risk scores in patients with atrial fibrillation taking warfarin","volume":"129","author":"Senoo","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.chest.2018.07.040_bib119","doi-asserted-by":"crossref","first-page":"24376","DOI":"10.1038\/srep24376","article-title":"Major bleeding in patients with non-valvular atrial fibrillation: impact of time in therapeutic range on contemporary bleeding risk scores","volume":"6","author":"Proietti","year":"2016","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib120","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib121","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/01.CIR.84.2.527","article-title":"Stroke Prevention in Atrial Fibrillation Study. Final results","volume":"84","year":"1991","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.chest.2018.07.040_bib122","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"Investigators","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"9526","key":"10.1016\/j.chest.2018.07.040_bib123","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"issue":"9921","key":"10.1016\/j.chest.2018.07.040_bib124","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib125","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib126","first-page":"587","article-title":"\u201cUnreal world\u201d or \u201creal world\u201d data in oral anticoagulant treatment of atrial fibrillation","volume":"116","author":"Freedman","year":"2016","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib127","first-page":"754","article-title":"Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists","volume":"116","author":"Carmo","year":"2016","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib128","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/STROKEAHA.116.016275","article-title":"Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis","volume":"48","author":"Bai","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.chest.2018.07.040_bib129","doi-asserted-by":"crossref","first-page":"i3189","DOI":"10.1136\/bmj.i3189","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"353","author":"Larsen","year":"2016","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib130","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/jamainternmed.2016.5954","article-title":"Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation","volume":"176","author":"Graham","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib131","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","article-title":"Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation","volume":"50","author":"Shen","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib132","first-page":"789","article-title":"Stroke prevention in atrial fibrillation: an Asian perspective","volume":"111","author":"Chiang","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.chest.2018.07.040_bib133","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijcard.2014.11.182","article-title":"Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal","volume":"180","author":"Lip","year":"2015","journal-title":"Int J Cardiol"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib134","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1161\/STROKEAHA.115.009947","article-title":"Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis","volume":"46","author":"Wang","year":"2015","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib135","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/STROKEAHA.115.011476","article-title":"Cardiovascular, bleeding, and mortality risks of dabigatran in Asians with nonvalvular atrial fibrillation","volume":"47","author":"Chan","year":"2016","journal-title":"Stroke"},{"issue":"13","key":"10.1016\/j.chest.2018.07.040_bib136","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jacc.2016.06.062","article-title":"Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation","volume":"68","author":"Chan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib137","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood-2016-09-692996","article-title":"Emerging anticoagulant strategies","volume":"129","author":"Fredenburgh","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib138","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/asheducation-2014.1.60","article-title":"Recent insights into the role of the contact pathway in thrombo-inflammatory disorders","volume":"2014","author":"van Montfoort","year":"2014","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib139","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/asheducation-2014.1.52","article-title":"Future prospects for contact factors as therapeutic targets","volume":"2014","author":"Gailani","year":"2014","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib140","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Buller","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2018.07.040_bib141","unstructured":"National Institutes of Health Clinical Center. NCT02553889. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02553889."},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib142","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.ahj.2012.03.011","article-title":"A\u00a0comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN)","volume":"163","author":"Van de Werf","year":"2012","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib143","first-page":"1087","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis\u2014Task Force on Anticoagulants in Heart Disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"issue":"suppl 2","key":"10.1016\/j.chest.2018.07.040_bib144","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib145","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa022913","article-title":"Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation","volume":"349","author":"Hylek","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib146","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-120-11-199406010-00001","article-title":"Risk factors for intracranial hemorrhage in outpatients taking warfarin","volume":"120","author":"Hylek","year":"1994","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib147","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1503\/cmaj.080171","article-title":"Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis","volume":"179","author":"Oake","year":"2008","journal-title":"CMAJ"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib148","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1253\/circj.CJ-12-0899","article-title":"Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment","volume":"77","author":"Hori","year":"2013","journal-title":"Circ J"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib149","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.STR.31.4.817","volume":"31","author":"Yamaguchi","year":"2000","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib150","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A\u00a0method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib151","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11239-007-0106-9","article-title":"Determinants and measures of quality in oral anticoagulation therapy","volume":"25","author":"Kaatz","year":"2008","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib152","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/bjh.14084","article-title":"Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists","volume":"174","author":"Fitzmaurice","year":"2016","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib153","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib154","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamacardio.2016.0199","article-title":"Outcomes in a warfarin-treated population with atrial fibrillation","volume":"1","author":"Bjorck","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib155","doi-asserted-by":"crossref","first-page":"e0164076","DOI":"10.1371\/journal.pone.0164076","article-title":"Quality of Vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry","volume":"11","author":"Haas","year":"2016","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib156","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11239-013-0900-5","article-title":"Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement","volume":"35","author":"Hylek","year":"2013","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"38","key":"10.1016\/j.chest.2018.07.040_bib157","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.chest.2018.07.040_bib158","unstructured":"National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance. Atrial Fibrillation: The Management of Atrial Fibrillation. London, United Kingdom: National Institute for Health and Care Excellence. Copyright National Clinical Guideline Centre, 2014; 2014."},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib159","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1177\/1747493016660106","article-title":"Overcoming global challenges in stroke prophylaxis in atrial fibrillation: the role of non-vitamin K antagonist oral anticoagulants","volume":"11","author":"Massaro","year":"2016","journal-title":"Int J Stroke"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib160","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/1062860614526282","article-title":"Explaining racial disparities in anticoagulation control: results from a study of patients at the Veterans Administration","volume":"30","author":"Rao","year":"2015","journal-title":"Am J Med Qual"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib161","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1538-7836.2012.04649.x","article-title":"INR targets and site-level anticoagulation control: results from the Veterans AffaiRs Study to Improve Anticoagulation (VARIA)","volume":"10","author":"Rose","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib162","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCOUTCOMES.110.960096","article-title":"Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care","volume":"4","author":"Rose","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib163","doi-asserted-by":"crossref","first-page":"e000521","DOI":"10.1161\/JAHA.113.000521","article-title":"Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial","volume":"3","author":"Piccini","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib164","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1253\/circj.CJ-15-0574","article-title":"Effects of regional differences in asia on efficacy and safety of edoxaban compared with warfarin\u2014insights from the ENGAGE AF-TIMI 48 Trial","volume":"79","author":"Shimada","year":"2015","journal-title":"Circ J"},{"issue":"19","key":"10.1016\/j.chest.2018.07.040_bib165","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1161\/CIRCULATIONAHA.112.101808","volume":"126","author":"Van Spall","year":"2012","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.chest.2018.07.040_bib166","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1161\/CIRCULATIONAHA.112.142158","article-title":"Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation","volume":"127","author":"Wallentin","year":"2013","journal-title":"Circulation"},{"issue":"9745","key":"10.1016\/j.chest.2018.07.040_bib167","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.chest.2018.07.040_bib168","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/jama.2015.2761","article-title":"Site-level variation in and practices associated with dabigatran adherence","volume":"313","author":"Shore","year":"2015","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib169","doi-asserted-by":"crossref","first-page":"e2895","DOI":"10.1097\/MD.0000000000002895","article-title":"Interaction between dietary vitamin K intake and anticoagulation by vitamin K antagonists: is it really true?: A systematic review","volume":"95","author":"Violi","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.chest.2018.07.040_bib170","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ahj.2018.03.004","article-title":"Time to therapeutic range (TtTR), anticoagulation control, and cardiovascular events in vitamin K antagonists-naive patients with atrial fibrillation","volume":"200","author":"Pastori","year":"2018","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib171","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.amjcard.2017.06.005","article-title":"Anticoagulation control in warfarin-treated patients undergoing cardioversion of atrial fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial)","volume":"120","author":"Lip","year":"2017","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib172","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib173","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.hrthm.2017.11.026","article-title":"Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients treated with vitamin K antagonists: a review","volume":"15","author":"Zulkifly","year":"2018","journal-title":"Heart Rhythm"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib174","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.08.030","article-title":"The Sex, Age, Medical History, Treatment, Tobacco Use, Race Risk (SAMe TT2R2) Score predicts warfarin control in a Singaporean population","volume":"26","author":"Bernaitis","year":"2017","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib175","doi-asserted-by":"crossref","first-page":"e0150674","DOI":"10.1371\/journal.pone.0150674","article-title":"Use of the SAMe-TT2R2 score to predict good anticoagulation control with warfarin in Chinese patients with atrial fibrillation: relationship to ischemic stroke incidence","volume":"11","author":"Chan","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.chest.2018.07.040_bib176","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.thromres.2016.09.021","article-title":"Evaluation of the SAMe-TT2R2 score to predict the quality of anticoagulation control in a cohort of patients with venous thromboembolism treated with vitamin K antagonists","volume":"147","author":"Demelo-Rodriguez","year":"2016","journal-title":"Thrombosis Res"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib177","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.amjmed.2014.05.023","article-title":"SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation","volume":"127","author":"Gallego","year":"2014","journal-title":"Am J Med"},{"issue":"7-8","key":"10.1016\/j.chest.2018.07.040_bib178","first-page":"494","article-title":"Assessment of the mean time in the therapeutic INR range and the SAME-TT2R2 score in patients with atrial fibrillation and cognitive impairment","volume":"126","author":"Gorzelak-Pabis","year":"2016","journal-title":"Polskie Archiwum Medycyny Wewnetrznej"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib179","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1378\/chest.13-2976","article-title":"Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation","volume":"146","author":"Lip","year":"2014","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.chest.2018.07.040_bib180","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1185\/03007995.2016.1164676","article-title":"Evaluation of SAMe-TT2R2 score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide study in Spain","volume":"32","author":"Lobos-Bejarano","year":"2016","journal-title":"Current Medical Research And Opinion"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib181","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11739-014-1065-8","article-title":"A\u00a0prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin","volume":"9","author":"Poli","year":"2014","journal-title":"Intern Emerg Med"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib182","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.amjmed.2015.05.036","article-title":"The SAMe-TT2R2 score predicts poor anticoagulation control in AF patients: a prospective \u2018real-world' inception cohort study","volume":"128","author":"Roldan","year":"2015","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib183","first-page":"695","article-title":"Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists","volume":"114","author":"Ruiz-Ortiz","year":"2015","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib184","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1378\/chest.13-1897","article-title":"SAMeTT(2)R(2) does not predict time in therapeutic range of the international normalized ratio in patients attending a high-quality anticoagulation clinic","volume":"145","author":"Skov","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.chest.2018.07.040_bib185","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ijcard.2015.11.158","article-title":"Usefulness of the SAME-TT2R2 score to predict anticoagulation control on VKA in patients with atrial fibrillation and obstructive sleep apnea","volume":"204","author":"Szymanski","year":"2016","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib186","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/europace\/euu353","article-title":"Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists","volume":"17","author":"Abumuaileq","year":"2015","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib187","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1358863X16682863","article-title":"SAMe-TT2R2 predicts quality of anticoagulation in patients with acute venous thromboembolism: The MAQI2 experience","volume":"22","author":"Kataruka","year":"2017","journal-title":"Vasc Med"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib188","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1160\/TH15-10-0830","article-title":"The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study","volume":"115","author":"Palareti","year":"2016","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib189","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.amjmed.2015.05.044","article-title":"National trends in ambulatory oral anticoagulant use","volume":"128","author":"Barnes","year":"2015","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib190","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1538-7836.2011.04568.x","article-title":"Precision and accuracy of point-of-care testing coagulometers used for self-testing and self-management of oral anticoagulation therapy","volume":"10","author":"Christensen","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.chest.2018.07.040_bib191","unstructured":"FDA. Food and Drug Administration. Point of Care PT\/INR Devices for Monitoring Warfarin Therapy. https:\/\/www.fda.gov\/downloads\/MedicalDevices\/NewsEvents\/WorkshopsConferences\/UCM491546.pdf. Accessed March 12,\u00a02017."},{"issue":"22","key":"10.1016\/j.chest.2018.07.040_bib192","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehs274","article-title":"Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"33","author":"Hohnloser","year":"2012","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib193","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s00392-017-1098-x","article-title":"Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study","volume":"106","author":"Hohnloser","year":"2017","journal-title":"Clin Res Cardiol"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib194","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cgh.2012.10.021","article-title":"Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial","volume":"11","author":"Bytzer","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.chest.2018.07.040_bib195","doi-asserted-by":"crossref","DOI":"10.1177\/2050312116662414","article-title":"Burden of upper gastrointestinal symptoms in patients prescribed dabigatran for stroke prevention","volume":"4","author":"Chan","year":"2016","journal-title":"SAGE Open Med"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib196","doi-asserted-by":"crossref","first-page":"e101245","DOI":"10.1371\/journal.pone.0101245","article-title":"Continuation of dabigatran therapy in \"real-world\" practice in Hong Kong","volume":"9","author":"Ho","year":"2014","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib197","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1160\/TH17-01-0068","article-title":"Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in \"real-world\" clinical practice. A propensity-matched analysis of 76,940 patients","volume":"117","author":"Li","year":"2017","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib198","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.amjcard.2017.07.072","article-title":"Meta-Analysis of Effectiveness and Safety of Oral Anticoagulants in Atrial Fibrillation With Focus on Apixaban","volume":"120","author":"Bai","year":"2017","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib199","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/europace\/euu311","article-title":"Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence","volume":"17","author":"Vrijens","year":"2015","journal-title":"Europace"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib200","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jfma.2017.05.015","article-title":"Once- or twice-daily non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: a meta-analysis of randomized controlled trials","volume":"116","author":"Wang","year":"2017","journal-title":"J\u00a0Formos Med Assoc"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib201","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.hrthm.2015.09.015","article-title":"Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation","volume":"13","author":"Chan","year":"2016","journal-title":"Heart Rhythm"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib202","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.116.004395","article-title":"Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a North American Perspective-2016 Update","volume":"9","author":"Angiolillo","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib203","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/europace\/euv233","volume":"17","author":"Lane","year":"2015","journal-title":"Europace"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib204","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/CIRCULATIONAHA.116.021831","article-title":"Management of bleeding with non-vitamin K antagonist oral anticoagulants in the era of specific reversal agents","volume":"134","author":"Ruff","year":"2016","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib205","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"issue":"13","key":"10.1016\/j.chest.2018.07.040_bib206","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2015.01.049","article-title":"Practical management of anticoagulation in patients with atrial fibrillation","volume":"65","author":"Kovacs","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib207","first-page":"1113","article-title":"Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants","volume":"114","author":"Weitz","year":"2015","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib208","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11239-015-1297-0","article-title":"Who, when, and how to reverse non-vitamin K oral anticoagulants","volume":"41","author":"Aronis","year":"2016","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib209","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40256-013-0055-y","article-title":"Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects","volume":"14","author":"Wang","year":"2014","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib210","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s13181-012-0276-5","article-title":"Positive outcome after intentional overdose of dabigatran","volume":"9","author":"Woo","year":"2013","journal-title":"J\u00a0Med Toxicol"},{"key":"10.1016\/j.chest.2018.07.040_bib211","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4137\/CCRep.S27992","article-title":"Accidental rivaroxaban overdose in a patient with pulmonary embolism: some lessons for managing new oral anticoagulants","volume":"8","author":"Sajkov","year":"2015","journal-title":"Clin Med Insights Case Rep"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib212","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib213","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/j.1538-7836.2012.04859.x","article-title":"Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P\/N) in a rabbit model","volume":"10","author":"Pragst","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib214","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/ALN.0b013e318238c036","article-title":"Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model","volume":"116","author":"Godier","year":"2012","journal-title":"Anesthesiology"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib215","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/j.1538-7836.2012.04863.x","article-title":"Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate","volume":"10","author":"Lambourne","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib216","first-page":"162","article-title":"Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates","volume":"110","author":"Perzborn","year":"2013","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib217","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1016\/j.ijcard.2013.07.152","article-title":"Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis","volume":"168","author":"Martin","year":"2013","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib218","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1161\/STROKEAHA.112.675231","article-title":"Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban","volume":"44","author":"Zhou","year":"2013","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib219","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1160\/TH14-08-0712","article-title":"Reversal of dabigatran anticoagulation ex\u00a0vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab","volume":"113","author":"Honickel","year":"2015","journal-title":"Thromb Haemost"},{"issue":"14","key":"10.1016\/j.chest.2018.07.040_bib220","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib221","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/jth.12599","article-title":"Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers","volume":"12","author":"Levi","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib222","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/CIRCULATIONAHA.114.013445","article-title":"Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate","volume":"131","author":"Zahir","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib223","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib224","first-page":"429","article-title":"Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis","volume":"106","author":"Dentali","year":"2011","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib225","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1365-2516.2002.00532.x","article-title":"Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events","volume":"8","author":"Ehrlich","year":"2002","journal-title":"Haemophilia"},{"issue":"18","key":"10.1016\/j.chest.2018.07.040_bib226","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A\u00a0specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.chest.2018.07.040_bib227","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1161\/CIRCULATIONAHA.115.019628","article-title":"Idarucizumab: the antidote for reversal of dabigatran","volume":"132","author":"Eikelboom","year":"2015","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib228","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal\u2014full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib229","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A\u00a0specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nature medicine"},{"key":"10.1016\/j.chest.2018.07.040_bib230","unstructured":"National Institutes of Health Clinical Center. NCT02329327. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02329327."},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib231","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2018.07.040_bib232","first-page":"75","article-title":"Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977","volume":"11","author":"Laulicht","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib233","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0002-8703(95)90045-4","article-title":"Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials","volume":"129","author":"Moreyra","year":"1995","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib234","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0735-1097(02)02052-1","article-title":"Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion","volume":"40","author":"Gallagher","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib235","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0002-9149(98)00704-8","article-title":"Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis","volume":"82","author":"Berger","year":"1998","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib236","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/0735-1097(89)90602-5","article-title":"Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation","volume":"13","author":"Manning","year":"1989","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.chest.2018.07.040_bib237","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijcard.2015.10.168","article-title":"Strokes after cardioversion of atrial fibrillation\u2014The FibStroke study","volume":"203","author":"Palomaki","year":"2016","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib238","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jamacardio.2016.4179","article-title":"Assessment of use vs\u00a0discontinuation of oral anticoagulation after pulmonary vein isolation in patients with atrial fibrillation","volume":"2","author":"Sj\u00e4lander","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib239","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jacc.2016.12.038","article-title":"Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease","volume":"69","author":"Renda","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib240","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/europace\/euv116","article-title":"Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey","volume":"17","author":"Larsen","year":"2015","journal-title":"Europace"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib241","first-page":"115","article-title":"Practical issues in the management of novel oral anticoagulants-cardioversion and ablation","volume":"7","author":"Maan","year":"2015","journal-title":"Journal of thoracic disease"},{"issue":"47","key":"10.1016\/j.chest.2018.07.040_bib242","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehu367","article-title":"Rivaroxaban vs. vitamin\u00a0K antagonists for cardioversion in atrial fibrillation","volume":"35","author":"Cappato","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.chest.2018.07.040_bib243","unstructured":"Xarelto. Summary of Product Characteristics. 2015; http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf. Accessed December 5,\u00a02016."},{"key":"10.1016\/j.chest.2018.07.040_bib244","unstructured":"Pradaxa. Summary of Product Characteristics. 2015; http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf. Accessed May 12,\u00a02016."},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib245","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00392-014-0797-9","article-title":"Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis","volume":"104","author":"Nielsen","year":"2015","journal-title":"Clin Res Cardiol"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib246","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/europace\/euv289","article-title":"Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis","volume":"18","author":"Chan","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.chest.2018.07.040_bib247","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ahj.2016.06.008","article-title":"Apixaban compared with parenteral heparin and\/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: rationale and design of the EMANATE trial","volume":"179","author":"Ezekowitz","year":"2016","journal-title":"Am Heart J"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib248","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1056\/NEJM199303183281102","article-title":"Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi","volume":"328","author":"Manning","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.chest.2018.07.040_bib249","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1056\/NEJM200105103441901","article-title":"Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation","volume":"344","author":"Klein","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.chest.2018.07.040_bib250","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s00392-015-0821-8","article-title":"Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis","volume":"104","author":"Caldeira","year":"2015","journal-title":"Clin Res Cardiol"},{"issue":"7","key":"10.1016\/j.chest.2018.07.040_bib251","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjcard.2008.05.025","article-title":"Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation","volume":"102","author":"Hoppensteadt","year":"2008","journal-title":"Am J Cardiol"},{"issue":"23","key":"10.1016\/j.chest.2018.07.040_bib252","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/eurheartj\/ehl353","volume":"27","author":"Klein","year":"2006","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib253","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ijcard.2004.05.052","article-title":"Pre- and post-cardioversion transesophageal echocardiography for brief anticoagulation therapy with enoxaparin in atrial fibrillation patients: a prospective study with a 1-year follow-up","volume":"102","author":"de Luca","year":"2005","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib254","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.amjmed.2005.06.029","article-title":"Safety of expedited anticoagulation in patients undergoing transesophageal echocardiographic-guided cardioversion","volume":"119","author":"Wu","year":"2006","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib255","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/01.CIR.0000120509.64740.DC","volume":"109","author":"Stellbrink","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib256","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1160\/th15-07-0532","article-title":"Prevalence of left atrial thrombus in patients with non-valvular atrial fibrillation. A systematic review and meta-analysis of the literature","volume":"115","author":"Di Minno","year":"2016","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib257","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.hrthm.2016.03.024","article-title":"Is transesophageal echocardiogram mandatory in patients undergoing ablation of atrial fibrillation with uninterrupted novel oral anticoagulants? Results from a prospective multicenter registry","volume":"13","author":"Di Biase","year":"2016","journal-title":"Heart Rhythm"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib258","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0735-1097(02)01800-4","article-title":"Clinical value of left atrial appendage flow for prediction of long-term sinus rhythm maintenance in patients with nonvalvular atrial fibrillation","volume":"39","author":"Antonielli","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib259","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0167-5273(01)00522-8","article-title":"Electrical cardioversion for atrial fibrillation: outcomes in \"real-life\" clinical practice","volume":"81","author":"Berry","year":"2001","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib260","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000177084","article-title":"Factors predicting maintenance of sinus rhythm after direct current cardioversion of atrial fibrillation and flutter: a reanalysis with recently acquired data","volume":"87","author":"Arnar","year":"1996","journal-title":"Cardiology"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib261","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1378\/chest.127.2.488","article-title":"Prediction of successful cardioversion and maintenance of sinus rhythm in patients with lone atrial fibrillation","volume":"127","author":"Paraskevaidis","year":"2005","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib262","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1001\/archinte.165.10.1185","article-title":"Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study","volume":"165","author":"Sherman","year":"2005","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib263","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/01.CIR.89.1.224","article-title":"Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia","volume":"89","author":"Page","year":"1994","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib264","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/0735-1097(94)00396-8","article-title":"Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study","volume":"25","author":"Stoddard","year":"1995","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib265","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.echo.2009.09.015","article-title":"Prevalence of left atrial thrombus and dense spontaneous echo contrast in patients with short-term atrial fibrillation\u00a0< 48 hours undergoing cardioversion: value of transesophageal echocardiography to guide cardioversion","volume":"22","author":"Kleemann","year":"2009","journal-title":"J\u00a0Am Soc Echocardiogr"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib266","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ahj.2004.06.032","article-title":"Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study","volume":"149","author":"Flaker","year":"2005","journal-title":"Am Heart J"},{"issue":"13","key":"10.1016\/j.chest.2018.07.040_bib267","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jacc.2013.04.089","article-title":"Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study","volume":"62","author":"Airaksinen","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib268","doi-asserted-by":"crossref","first-page":"615","DOI":"10.7326\/0003-4819-126-8-199704150-00005","article-title":"Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours","volume":"126","author":"Weigner","year":"1997","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib269","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0196-0644(99)70300-8","article-title":"Cardioversion of paroxysmal atrial fibrillation in the emergency department","volume":"33","author":"Michael","year":"1999","journal-title":"Ann Emerg Med"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib270","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.annemergmed.2004.02.016","article-title":"Electrical cardioversion of emergency department patients with atrial fibrillation","volume":"44","author":"Burton","year":"2004","journal-title":"Ann Emerg Med"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib271","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1017\/S1481803500012227","article-title":"Association of the Ottawa Aggressive Protocol with rapid discharge of emergency department patients with recent-onset atrial fibrillation or flutter","volume":"12","author":"Stiell","year":"2010","journal-title":"CJEM"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib272","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1553-2712.2010.00697.x","article-title":"Thirty-day outcomes of emergency department patients undergoing electrical cardioversion for atrial fibrillation or flutter","volume":"17","author":"Xavier Scheuermeyer","year":"2010","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.chest.2018.07.040_bib273","article-title":"Predicting Unsuccessful Electrical Cardioversion for Acute Atrial Fibrillation (from the AF-CVS Score)","author":"Jaakkola","year":"2016","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib274","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0735-1097(92)90530-Z","article-title":"Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter","volume":"19","author":"Arnold","year":"1992","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib275","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0002-9149(97)89328-9","article-title":"Direct-current cardioversion for the conversion of atrial flutter","volume":"77","author":"Chalasani","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.chest.2018.07.040_bib276","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijcard.2017.01.001","article-title":"Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: the ARAPACIS Study","volume":"231","author":"Basili","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.chest.2018.07.040_bib277","doi-asserted-by":"crossref","unstructured":"Lip GYH, Collet JP, Haude M, et\u00a0al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: A joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS) and Cardiac Arrhythmia Society of Southern Africa (CASSA) [published online ahead of print July 21, 2018]. Europace. https:\/\/doi.org\/10.1093\/europace\/euy174.","DOI":"10.1093\/europace\/euy174"},{"key":"10.1016\/j.chest.2018.07.040_bib278","unstructured":"Bonaca MP, Goto S, Bhatt DL, et\u00a0al. Prevention of stroke with ticagrelor in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). (1524-4539 (Electronic))."},{"key":"10.1016\/j.chest.2018.07.040_bib279","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ahj.2017.05.016","article-title":"Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: the Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry","volume":"190","author":"Proietti","year":"2017","journal-title":"Am Heart J"},{"issue":"50","key":"10.1016\/j.chest.2018.07.040_bib280","doi-asserted-by":"crossref","first-page":"e5581","DOI":"10.1097\/MD.0000000000005581","volume":"95","author":"Chaudhary","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"46","key":"10.1016\/j.chest.2018.07.040_bib281","doi-asserted-by":"crossref","first-page":"81154","DOI":"10.18632\/oncotarget.20870","article-title":"Efficacy and safety of triple versus dual antithrombotic therapy in atrial fibrillation and ischemic heart disease: a systematic review and meta-analysis","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib282","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1161\/CIRCULATIONAHA.117.028513","article-title":"Efficacy and safety of the use of non-vitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation and concomitant aspirin therapy: a meta-analysis of randomized trials","volume":"137","author":"Bennaghmouch","year":"2018","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib283","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9872","key":"10.1016\/j.chest.2018.07.040_bib284","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.chest.2018.07.040_bib285","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE Trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.chest.2018.07.040_bib286","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib287","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.116.025783","article-title":"Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy","volume":"135","author":"Gibson","year":"2017","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.chest.2018.07.040_bib288","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.chest.2018.07.040_bib289","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","article-title":"Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation","volume":"61","author":"Sarafoff","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.chest.2018.07.040_bib290","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)30751-1","article-title":"Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial","author":"Ohman","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib291","article-title":"Using the CHA2DS2-VASc score for stroke prevention in atrial fibrillation: a focus on vascular disease, women, and simple practical application","volume":"31","author":"Nielsen","year":"2015","journal-title":"Can J Cardiol"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib292","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.atherosclerosis.2011.03.033","article-title":"Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation\u2014a nation wide database analysis","volume":"217","author":"Lin","year":"2011","journal-title":"Atherosclerosis"},{"issue":"15","key":"10.1016\/j.chest.2018.07.040_bib293","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.113.004834","article-title":"Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study","volume":"129","author":"Lamberts","year":"2014","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib294","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CRD.0000000000000088","article-title":"Non-vitamin K antagonist oral anticoagulants and antiplatelet therapy for stroke prevention in patients with atrial fibrillation: a meta-analysis of randomized controlled trials","volume":"24","author":"Kumar","year":"2016","journal-title":"Cardiol Rev"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib295","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib296","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/eurheartj\/eht492","article-title":"Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF","volume":"35","author":"Jones","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib297","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/europace\/eux274","article-title":"2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation","volume":"20","author":"Calkins","year":"2018","journal-title":"Europace"},{"issue":"25","key":"10.1016\/j.chest.2018.07.040_bib298","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1161\/CIRCULATIONAHA.113.006426","volume":"129","author":"Di Biase","year":"2014","journal-title":"Circulation"},{"issue":"28","key":"10.1016\/j.chest.2018.07.040_bib299","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","article-title":"Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation","volume":"36","author":"Cappato","year":"2015","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.chest.2018.07.040_bib300","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1701005","article-title":"Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation","volume":"376","author":"Calkins","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2018.07.040_bib301","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ahj.2015.12.007","article-title":"Strategy of continued vs\u00a0interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: the BRUISE CONTROL-2 trial","volume":"173","author":"Essebag","year":"2016","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib302","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.hrthm.2017.09.011","article-title":"An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation","volume":"15","author":"Cardoso","year":"2018","journal-title":"Heart Rhythm"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib303","first-page":"814","article-title":"Uninterrupted new oral anticoagulants compared with uninterrupted vitamin K antagonists in ablation of atrial fibrillation: a meta-analysis","volume":"32","author":"Nairooz","year":"2016","journal-title":"Can J Cardiol"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib304","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.hrthm.2011.04.022","article-title":"Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS","volume":"8","author":"Daoud","year":"2011","journal-title":"Heart Rhythm"},{"issue":"21","key":"10.1016\/j.chest.2018.07.040_bib305","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/CIRCULATIONAHA.113.007825","article-title":"Temporal relationship between subclinical atrial fibrillation and embolic events","volume":"129","author":"Brambatti","year":"2014","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib306","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1001\/jama.2014.9143","article-title":"Perioperative atrial fibrillation and the long-term risk of ischemic stroke","volume":"312","author":"Gialdini","year":"2014","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib307","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1161\/hs1001.097093","article-title":"Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial","volume":"32","author":"Saxena","year":"2001","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib308","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1161\/01.STR.14.5.688","article-title":"Early recurrent embolism associated with nonvalvular atrial fibrillation: a retrospective study","volume":"14","author":"Hart","year":"1983","journal-title":"Stroke"},{"issue":"9211","key":"10.1016\/j.chest.2018.07.040_bib309","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(00)02085-7","article-title":"Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial","volume":"355","author":"Berge","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib310","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1161\/01.STR.0000254600.92975.1f","article-title":"Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials","volume":"38","author":"Paciaroni","year":"2007","journal-title":"Stroke"},{"issue":"9066","key":"10.1016\/j.chest.2018.07.040_bib311","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(97)04010-5","article-title":"CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group","volume":"349","year":"1997","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib312","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/01.STR.27.10.1760","article-title":"Stroke severity in atrial fibrillation. The Framingham Study","volume":"27","author":"Lin","year":"1996","journal-title":"Stroke"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib313","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1161\/STROKEAHA.107.510321","article-title":"Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study","volume":"39","author":"Paciaroni","year":"2008","journal-title":"Stroke"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib314","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1161\/STROKEAHA.115.008891","article-title":"Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF Study","volume":"46","author":"Paciaroni","year":"2015","journal-title":"Stroke"},{"issue":"7","key":"10.1016\/j.chest.2018.07.040_bib315","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/ene.12577","article-title":"Association of improved outcome in acute ischaemic stroke patients with atrial fibrillation who receive early antithrombotic therapy: analysis from VISTA","volume":"22","author":"Abdul-Rahim","year":"2015","journal-title":"Eur J Neurol"},{"issue":"7","key":"10.1016\/j.chest.2018.07.040_bib316","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib317","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.5603\/KP.2016.0172","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS [in Polish]","volume":"74","author":"Kirchhof","year":"2016","journal-title":"Kardiol Pol"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib318","first-page":"410","article-title":"Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation","volume":"116","author":"Paciaroni","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.chest.2018.07.040_bib319","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12883-014-0199-7","article-title":"Management of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt)","volume":"14","author":"Palm","year":"2014","journal-title":"BMC neurology"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib320","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/archneur.56.9.1098","article-title":"Heparin in acute stroke with atrial fibrillation: clinical relevance of very early treatment","volume":"56","author":"Chamorro","year":"1999","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib321","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1017\/cjn.2015.7","article-title":"Early Anti-coagulation after ischemic stroke due to atrial fibrillation is safe and prevents recurrent stroke","volume":"42","author":"Hahn","year":"2015","journal-title":"Can J Neurol Sci"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib322","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1001\/archneur.65.9.noc70105","article-title":"Anticoagulation after cardioembolic stroke: to bridge or not to bridge?","volume":"65","author":"Hallevi","year":"2008","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib323","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/jth.12810","article-title":"Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non-valvular atrial fibrillation patients: a multicenter propensity-matched analysis","volume":"13","author":"Kim","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib324","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000145324","article-title":"Initiation of oral anticoagulation after acute ischaemic stroke or transient ischaemic attack: timing and complications of overlapping heparin or conventional treatment","volume":"26","author":"Audebert","year":"2008","journal-title":"Cerebrovasc Dis"},{"issue":"18","key":"10.1016\/j.chest.2018.07.040_bib325","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1212\/WNL.0000000000003283","article-title":"Early start of DOAC after ischemic stroke: Risk of intracranial hemorrhage and recurrent events","volume":"87","author":"Seiffge","year":"2016","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib326","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/ijs.12452","article-title":"Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study","volume":"10","author":"Toyoda","year":"2015","journal-title":"Int J Stroke"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib327","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/1747493016632239","article-title":"Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: the SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study","volume":"11","author":"Arihiro","year":"2016","journal-title":"Int J Stroke"},{"key":"10.1016\/j.chest.2018.07.040_bib328","article-title":"Antikoagulantia efter akut ischemisk stroke med f\u00f6rmaksflimmer\u2014Fr\u00e5gan om r\u00e4tt tidpunkt f\u00f6r ins\u00e4ttning kr\u00e4ver randomiserad klinisk pr\u00f6vning [in Swedish]","volume":"113","author":"Terent","year":"2016","journal-title":"Lakartidningen"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib329","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/ijs.12386","article-title":"Rationale and design of Triple AXEL: trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation","volume":"10","author":"Hong","year":"2015","journal-title":"Int J Stroke"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib330","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1474-4422(07)70107-2","article-title":"Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study","volume":"6","author":"Lovelock","year":"2007","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib331","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/ene.12215","article-title":"Prevalence of atrial fibrillation in intracerebral hemorrhage","volume":"21","author":"Horstmann","year":"2014","journal-title":"Eur J Neurol"},{"issue":"16","key":"10.1016\/j.chest.2018.07.040_bib332","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/CIRCULATIONAHA.115.019794","article-title":"Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage","volume":"133","author":"Chao","year":"2016","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib333","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2013-306476","article-title":"Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis","volume":"85","author":"Poon","year":"2014","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.chest.2018.07.040_bib334","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jns.2016.11.021","article-title":"The Cerebral Haemorrhage Anatomical RaTing inStrument (CHARTS): development and assessment of reliability","volume":"372","author":"Charidimou","year":"2017","journal-title":"J\u00a0Neurol Sci"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib335","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1212\/WNL.56.4.537","article-title":"Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria","volume":"56","author":"Knudsen","year":"2001","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib336","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1212\/WNL.0000000000004259","article-title":"Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds: a meta-analysis","volume":"89","author":"Charidimou","year":"2017","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.chest.2018.07.040_bib337","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1212\/WNL.0000000000003183","article-title":"Recurrent stroke risk and cerebral microbleed burden in ischemic stroke and TIA: a meta-analysis","volume":"87","author":"Wilson","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib338","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/WCO.0000000000000411","article-title":"Antithrombotic therapy in patients with cerebral microbleeds","volume":"30","author":"Wilson","year":"2017","journal-title":"Curr Opin Neurol"},{"issue":"7","key":"10.1016\/j.chest.2018.07.040_bib339","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1161\/01.STR.0000078311.18928.16","article-title":"Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis","volume":"34","author":"Eckman","year":"2003","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib340","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/STROKEAHA.116.016327","article-title":"Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis","volume":"48","author":"Murthy","year":"2017","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib341","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/NRL.0b013e3181a93bac","article-title":"Prevention of deep venous thrombosis and pulmonary embolism in patients with acute intracerebral hemorrhage","volume":"15","author":"Orken","year":"2009","journal-title":"Neurologist"},{"issue":"23","key":"10.1016\/j.chest.2018.07.040_bib342","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/BF01727666","article-title":"Heparin therapy, deep-vein thrombosis and pulmonary embolism after intracerebral hemorrhage","volume":"66","author":"Dickmann","year":"1988","journal-title":"Klin Wochenschr"},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib343","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/STROKEAHA.110.593087","article-title":"Optimal timing of resumption of warfarin after intracranial hemorrhage","volume":"41","author":"Majeed","year":"2010","journal-title":"Stroke"},{"issue":"18","key":"10.1016\/j.chest.2018.07.040_bib344","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1212\/WNL.0000000000003886","article-title":"Outcome of intracerebral hemorrhage associated with different oral anticoagulants","volume":"88","author":"Wilson","year":"2017","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib345","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/europace\/euu069","article-title":"Ischaemic stroke prevention in patients with atrial fibrillation and high bleeding risk: opportunities and challenges for percutaneous left atrial appendage occlusion","volume":"16","author":"Lewalter","year":"2014","journal-title":"Europace"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib346","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.hrthm.2017.05.038","article-title":"Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial","volume":"14","author":"Boersma","year":"2017","journal-title":"Heart Rhythm"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib347","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.11.126","article-title":"Left Atrial Appendage Closure in Patients with Atrial Fibrillation and Previous Intracerebral Hemorrhage","volume":"26","author":"Renou","year":"2017","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib348","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1212\/WNL.0000000000000022","article-title":"Left atrial appendage occlusion in atrial fibrillation after intracranial hemorrhage","volume":"82","author":"Horstmann","year":"2014","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib349","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1468-1331.2002.00423.x","article-title":"Prevalence and outcome of asymptomatic carotid stenosis: a population-based ultrasonographic study","volume":"9","author":"Mineva","year":"2002","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib350","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/ene.13280","article-title":"Stroke recurrence in patients with atrial fibrillation: concomitant carotid artery stenosis doubles the risk","volume":"24","author":"Lehtola","year":"2017","journal-title":"Eur J Neurol"},{"issue":"9967","key":"10.1016\/j.chest.2018.07.040_bib351","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(14)61184-3","article-title":"Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial","volume":"385","author":"Bonati","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib352","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1056\/NEJMc1609156","article-title":"Cryptogenic stroke","volume":"375","author":"Saver","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib353","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1474-4422(13)70310-7","article-title":"Embolic strokes of undetermined source: the case for a new clinical construct","volume":"13","author":"Hart","year":"2014","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib354","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/STROKEAHA.116.016414","article-title":"embolic stroke of undetermined source: a systematic review and clinical update","volume":"48","author":"Hart","year":"2017","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib355","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S1474-4422(15)70027-X","article-title":"Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis","volume":"14","author":"Sposato","year":"2015","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib356","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1161\/STROKEAHA.106.478685","article-title":"Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review","volume":"38","author":"Liao","year":"2007","journal-title":"Stroke"},{"issue":"26","key":"10.1016\/j.chest.2018.07.040_bib357","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1056\/NEJMoa1313600","article-title":"Cryptogenic stroke and underlying atrial fibrillation","volume":"370","author":"Sanna","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.chest.2018.07.040_bib358","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1056\/NEJMoa1311376","article-title":"Atrial fibrillation in patients with cryptogenic stroke","volume":"370","author":"Gladstone","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib359","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.116.002864","article-title":"Atrial fibrillation diagnosis timing, ambulatory ECG monitoring utilization, and risk of recurrent stroke","volume":"10","author":"Lip","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib360","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/pace.12688","article-title":"Role of outpatient cardiac rhythm monitoring in cryptogenic stroke: a systematic review and meta-analysis","volume":"38","author":"Afzal","year":"2015","journal-title":"Pacing Clin Electrophysiol"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib361","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/STROKEAHA.114.007763","article-title":"Predictors of finding occult atrial fibrillation after cryptogenic stroke","volume":"46","author":"Favilla","year":"2015","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib362","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.amjcard.2012.06.034","article-title":"Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring in primary stroke prevention","volume":"110","author":"Ziegler","year":"2012","journal-title":"Am J Cardiol"},{"issue":"14","key":"10.1016\/j.chest.2018.07.040_bib363","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1161\/CIRCULATIONAHA.117.028845","article-title":"Subclinical atrial fibrillation in older patients","volume":"136","author":"Healey","year":"2017","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib364","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0b013e318287281b","article-title":"CHADS(2), CHA(2)S(2)DS(2)-VASc, and long-term stroke outcome in patients without atrial fibrillation","volume":"80","author":"Ntaios","year":"2013","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib365","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.08.015","article-title":"Embolic stroke of undetermined source and detection of atrial fibrillation on follow-up: how much causality is there?","volume":"25","author":"Ntaios","year":"2016","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib366","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1212\/WNL.0000000000004199","article-title":"Age- and sex-specific analysis of patients with embolic stroke of undetermined source","volume":"89","author":"Ntaios","year":"2017","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib367","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/europace\/eux163","volume":"19","author":"Gorenek","year":"2017","journal-title":"Europace"},{"key":"10.1016\/j.chest.2018.07.040_bib368","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.vph.2016.03.006","article-title":"Atrial fibrillation burden and atrial fibrillation type: Clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation","volume":"83","author":"Boriani","year":"2016","journal-title":"Vasc Pharmacol"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib369","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/europace\/eux177","volume":"19","author":"Mairesse","year":"2017","journal-title":"Europace"},{"issue":"19","key":"10.1016\/j.chest.2018.07.040_bib370","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1161\/CIRCULATIONAHA.116.026693","article-title":"Screening for atrial fibrillation: a report of the AF-SCREEN International Collaboration","volume":"135","author":"Freedman","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib371","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1105575","article-title":"Subclinical atrial fibrillation and the risk of stroke","volume":"366","author":"Healey","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib372","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrcardio.2017.94","article-title":"Management of atrial high-rate episodes detected by cardiac implanted electronic devices","volume":"14","author":"Freedman","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib373","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2174\/1381612820666140825142639","article-title":"Asymptomatic lone atrial fibrillation\u2014how can we detect the arrhythmia?","volume":"21","author":"Boriani","year":"2015","journal-title":"Curr Pharmaceut Design"},{"issue":"4 pt 1","key":"10.1016\/j.chest.2018.07.040_bib374","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1460-9592.2001.00424.x","article-title":"Clinical utility of intraatrial pacemaker stored electrograms to diagnose atrial fibrillation and flutter","volume":"24","author":"Pollak","year":"2001","journal-title":"Pacing Clin Electrophysiol"},{"issue":"7","key":"10.1016\/j.chest.2018.07.040_bib375","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1540-8159.2004.00569.x","article-title":"Accuracy of atrial tachyarrhythmia detection in implantable devices with arrhythmia therapies","volume":"27","author":"Purerfellner","year":"2004","journal-title":"Pacing Clin Electrophysiol"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib376","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/ijcp.12326","article-title":"AF burden is important\u2014fact or fiction?","volume":"68","author":"Boriani","year":"2014","journal-title":"Int J Clin Pract"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib377","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrcardio.2015.30","article-title":"Management of atrial fibrillation in bradyarrhythmias","volume":"12","author":"Boriani","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib378","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1161\/CIRCEP.114.001356","article-title":"Role of atrial fibrillation burden in assessing thromboembolic risk","volume":"7","author":"Zimetbaum","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"16","key":"10.1016\/j.chest.2018.07.040_bib379","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1161\/CIRCULATIONAHA.115.020252","article-title":"Clinical implications of brief device-detected atrial tachyarrhythmias in a cardiac rhythm management device population: results from the Registry of Atrial Tachycardia and Atrial Fibrillation Episodes","volume":"134","author":"Swiryn","year":"2016","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib380","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/01.CIR.0000057981.70380.45","article-title":"Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST)","volume":"107","author":"Glotzer","year":"2003","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib381","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.jacc.2005.07.044","article-title":"Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers","volume":"46","author":"Capucci","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib382","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1540-8167.2008.01320.x","article-title":"Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events","volume":"20","author":"Botto","year":"2009","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib383","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/CIRCEP.109.849638","article-title":"The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study","volume":"2","author":"Glotzer","year":"2009","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib384","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/europace\/eur293","article-title":"Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure-cardiac resynchronization therapy population","volume":"14","author":"Shanmugam","year":"2012","journal-title":"Europace"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib385","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/eurheartj\/eht491","article-title":"Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices)","volume":"35","author":"Boriani","year":"2014","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib386","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.hrthm.2014.08.019","article-title":"Newly detected atrial high rate episodes predict long-term mortality outcomes in patients with permanent pacemakers","volume":"11","author":"Gonzalez","year":"2014","journal-title":"Heart Rhythm"},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib387","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.hrthm.2015.07.007","article-title":"Early detection of atrial high rate episodes predicts atrial fibrillation and thromboembolic events in patients with cardiac resynchronization therapy","volume":"12","author":"Witt","year":"2015","journal-title":"Heart Rhythm"},{"issue":"17","key":"10.1016\/j.chest.2018.07.040_bib388","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/eurheartj\/ehx042","article-title":"Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT","volume":"38","author":"Van Gelder","year":"2017","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib389","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/STROKEAHA.110.609297","article-title":"Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring","volume":"42","author":"Boriani","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.chest.2018.07.040_bib390","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ahj.2017.04.008","article-title":"Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial","volume":"189","author":"Lopes","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.chest.2018.07.040_bib391","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ahj.2017.04.015","article-title":"Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial","volume":"190","author":"Kirchhof","year":"2017","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib392","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0002-9149(98)00419-6","article-title":"Risk of thromboembolic events in patients with atrial flutter","volume":"82","author":"Seidl","year":"1998","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.chest.2018.07.040_bib393","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1053\/euhj.2000.2427","article-title":"Thromboembolic risk in atrial flutter. The FLASIEC (FLutter Atriale Societa Italiana di Ecografia Cardiovascolare) multicentre study","volume":"22","author":"Corrado","year":"2001","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib394","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.hrthm.2015.04.015","article-title":"New-generation atrial antitachycardia pacing (Reactive ATP) is associated with reduced risk of persistent or permanent atrial fibrillation in patients with bradycardia: results from the MINERVA randomized multicenter international trial","volume":"12","author":"Padeletti","year":"2015","journal-title":"Heart Rhythm"},{"issue":"18","key":"10.1016\/j.chest.2018.07.040_bib395","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1136\/heartjnl-2015-307550","article-title":"Atrial flutter and thromboembolic risk: a systematic review","volume":"101","author":"Vadmann","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.chest.2018.07.040_bib396","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/0002-9149(64)90112-2","article-title":"Experience with \"cardioversion\" of atrial fibrillation and flutter","volume":"14","author":"Morris","year":"1964","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib397","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1001\/jama.1965.03090240015003","article-title":"Electroshock for atrial flutter and atrial fibrillation. Follow-up studies on 50 patients","volume":"194","author":"Jensen","year":"1965","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib398","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.0954-6820.1967.tb10893.x","article-title":"Atrial fibrillation and flutter treated with synchronized DC shock. A study on immediate and long-term results","volume":"182","author":"Wikland","year":"1967","journal-title":"Acta medica Scandinavica"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib399","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.0954-6820.1968.tb02489.x","article-title":"An evaluation of DC shock treatment of atrial arrhythmias","volume":"184","author":"Bjerkelund","year":"1968","journal-title":"Acta Med Scand"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib400","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0735-1097(97)00326-4","article-title":"Thromboembolism in chronic atrial flutter: is the risk underestimated?","volume":"30","author":"Lanzarotti","year":"1997","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib401","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/hrt.77.1.56","article-title":"Long-term outcome of electrical cardioversion in patients with chronic atrial flutter","volume":"77","author":"Crijns","year":"1997","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib402","first-page":"349","article-title":"Cardioversion of persistent atrial flutter in non-anticoagulated patients at low risk for thromboembolism","volume":"1","author":"Bertaglia","year":"2000","journal-title":"Italian Heart Journal"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib403","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0002-9343(01)00902-0","article-title":"Thromboembolic complications after electrical cardioversion in patients with atrial flutter","volume":"111","author":"Elhendy","year":"2001","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib404","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.annemergmed.2010.09.027","article-title":"Emergency department management and 1-year outcomes of patients with atrial flutter","volume":"57","author":"Scheuermeyer","year":"2011","journal-title":"Ann Emerg Med"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib405","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2013.12.044","article-title":"Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter","volume":"113","author":"Yadlapati","year":"2014","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib406","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0735-1097(94)90557-6","article-title":"Left atrial appendage function and thrombus formation in atrial fibrillation-flutter: a transesophageal echocardiographic study","volume":"24","author":"Santiago","year":"1994","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib407","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/0735-1097(94)90121-X","article-title":"Transesophageal echocardiographic detection of atrial thrombi in patients with nonfibrillation atrial tachyarrhythmias and congenital heart disease","volume":"24","author":"Feltes","year":"1994","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib408","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0002-9149(99)80058-7","article-title":"Prevalence of intraatrial thrombus in patients with atrial flutter","volume":"76","author":"Bikkina","year":"1995","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib409","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/0002-8703(95)90253-8","article-title":"Left atrial appendage \"stunning\" after spontaneous conversion of atrial fibrillation demonstrated by transesophageal Doppler echocardiography","volume":"130","author":"Grimm","year":"1995","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib410","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/01.CIR.95.4.962","article-title":"Prevalence of thrombus, spontaneous echo contrast, and atrial stunning in patients undergoing cardioversion of atrial flutter. A prospective study using transesophageal echocardiography","volume":"95","author":"Irani","year":"1997","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib411","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0002-9149(98)00555-4","article-title":"Acute changes in spontaneous echo contrast and atrial function after cardioversion of persistent atrial flutter","volume":"82","author":"Weiss","year":"1998","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib412","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0735-1097(01)01463-2","article-title":"Prevalence of left atrial chamber and appendage thrombi in patients with atrial flutter and its clinical significance","volume":"38","author":"Schmidt","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1 pt 2","key":"10.1016\/j.chest.2018.07.040_bib413","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1460-9592.2003.00042.x","article-title":"Thromboembolic risk of patients referred for radiofrequency catheter ablation of typical atrial flutter without prior appropriate anticoagulation therapy","volume":"26","author":"Gronefeld","year":"2003","journal-title":"Pacing Clin Electrophysiol"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib414","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.amjcard.2011.10.007","article-title":"Usefulness of transesophageal echocardiography to confirm clinical utility of CHA2DS2-VASc and CHADS2 scores in atrial flutter","volume":"109","author":"Parikh","year":"2012","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib415","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.echo.2013.05.017","article-title":"Transesophageal echocardiographic screening before atrial flutter ablation: is it necessary for patient safety?","volume":"26","author":"Alyeshmerni","year":"2013","journal-title":"J\u00a0Am Soc Echocardiogr"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib416","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0002-9149(97)00044-1","article-title":"Risk of thromboembolism in chronic atrial flutter","volume":"79","author":"Wood","year":"1997","journal-title":"Am J Cardiol"},{"issue":"24","key":"10.1016\/j.chest.2018.07.040_bib417","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/eurheartj\/ehr218","article-title":"ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)","volume":"32","author":"Regitz-Zagrosek","year":"2011","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib418","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1080\/03007995.2017.1330257","article-title":"Atrial fibrillation in pregnancy: a growing challenge","volume":"33","author":"Katsi","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib419","doi-asserted-by":"crossref","first-page":"e0133466","DOI":"10.1371\/journal.pone.0133466","article-title":"Pregnancy-associated heart failure: a comparison of clinical presentation and outcome between hypertensive heart failure of pregnancy and idiopathic peripartum cardiomyopathy","volume":"10","author":"Ntusi","year":"2015","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib420","doi-asserted-by":"crossref","first-page":"e003182","DOI":"10.1161\/JAHA.115.003182","article-title":"Atrial fibrillation and atrial flutter in pregnant women\u2014a population-based study","volume":"5","author":"Lee","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"2 Suppl","key":"10.1016\/j.chest.2018.07.040_bib421","doi-asserted-by":"crossref","first-page":"e691S","DOI":"10.1378\/chest.11-2300","article-title":"VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Bates","year":"2012","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib422","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccl.2012.05.003","article-title":"Anticoagulation in pregnancy","volume":"30","author":"Goland","year":"2012","journal-title":"Cardiol Clin"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib423","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11239-013-0941-9","article-title":"Pulmonary embolism in pregnancy","volume":"37","author":"Conti","year":"2014","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"6076","key":"10.1016\/j.chest.2018.07.040_bib424","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1136\/bmj.1.6076.1564","article-title":"May mothers given warfarin breast-feed their infants?","volume":"1","author":"Orme","year":"1977","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib425","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0022-3476(83)80378-3","article-title":"Is warfarin sodium contraindicated in the lactating mother?","volume":"103","author":"McKenna","year":"1983","journal-title":"J\u00a0Pediatr"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib426","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00609589","article-title":"May mothers taking acenocoumarol breast feed their infants?","volume":"21","author":"Houwert-de Jong","year":"1981","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib427","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0049-3848(89)90005-4","article-title":"Effect of acenocoumarine on the breast-fed infant","volume":"56","author":"Fondevila","year":"1989","journal-title":"Thrombosis Res"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib428","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/europace\/euv202","volume":"17","author":"Boriani","year":"2015","journal-title":"Europace"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib429","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/heartjnl-2016-309266","article-title":"Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease","volume":"103","author":"Yang","year":"2017","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib430","first-page":"243","article-title":"Are Existing Risk Scores for Nonvalvular Atrial Fibrillation Useful for Prediction or Risk Adjustment in Patients With Chronic Kidney Disease?","volume":"33","author":"McAlister","year":"2017","journal-title":"Can J Cardiol"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib431","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.hrthm.2014.06.021","article-title":"Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis","volume":"11","author":"Chao","year":"2014","journal-title":"Heart Rhythm"},{"issue":"9","key":"10.1016\/j.chest.2018.07.040_bib432","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1001\/jama.2014.1334","article-title":"Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation","volume":"311","author":"Carrero","year":"2014","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib433","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/eurheartj\/ehu139","article-title":"Balancing stroke and bleeding risks\u00a0in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study","volume":"36","author":"Friberg","year":"2015","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.chest.2018.07.040_bib434","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2014.09.051","article-title":"Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study","volume":"64","author":"Bonde","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib435","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jacc.2016.11.031","article-title":"Effect of reduced renal function on time in therapeutic range among anticoagulated atrial fibrillation patients","volume":"69","author":"Bonde","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib436","first-page":"737","article-title":"Warfarin and the risk of stroke and bleeding in patients with atrial fibrillation receiving dialysis: a systematic review and meta-analysis","volume":"33","author":"Harel","year":"2017","journal-title":"Can J Cardiol"},{"issue":"13","key":"10.1016\/j.chest.2018.07.040_bib437","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.jacc.2016.06.057","article-title":"Atrial fibrillation and thromboembolism in patients with chronic kidney disease","volume":"68","author":"Lau","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.chest.2018.07.040_bib438","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euu178","article-title":"The definition of valvular and non-valvular atrial fibrillation: results of a physicians' survey","author":"Molteni","year":"2014","journal-title":"Europace"},{"issue":"39","key":"10.1016\/j.chest.2018.07.040_bib439","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"issue":"13","key":"10.1016\/j.chest.2018.07.040_bib440","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 3","key":"10.1016\/j.chest.2018.07.040_bib441","article-title":"Abstract 17277: apixaban use in patients with atrial fibrillation with bioprosthetic valves: insights from ARISTOTLE","volume":"132","author":"Pokorney","year":"2015","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.chest.2018.07.040_bib442","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1161\/CIRCULATIONAHA.116.026714","article-title":"Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves","volume":"135","author":"Carnicelli","year":"2017","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.chest.2018.07.040_bib443","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.4244\/EIJ-D-16-00678","article-title":"Current status of transcatheter mitral valve therapy in Europe: results from an EAPCI survey (Part II)","volume":"12","author":"Petronio","year":"2017","journal-title":"EuroIntervention"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib444","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/euv288","article-title":"Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial","volume":"18","author":"De Caterina","year":"2016","journal-title":"Europace"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib445","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","article-title":"Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation","volume":"61","author":"Blackshear","year":"1996","journal-title":"Ann Thoracic Surg"},{"issue":"19","key":"10.1016\/j.chest.2018.07.040_bib446","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1001\/jama.2014.15192","article-title":"Percutaneous left atrial appendage closure vs\u00a0warfarin for atrial fibrillation: a randomized clinical trial","volume":"312","author":"Reddy","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib447","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/CIRCULATIONAHA.112.114389","article-title":"Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial","volume":"127","author":"Reddy","year":"2013","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.chest.2018.07.040_bib448","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.110.976449","article-title":"Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry","volume":"123","author":"Reddy","year":"2011","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.chest.2018.07.040_bib449","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.amjcard.2016.01.039","article-title":"Assessment of device-related thrombus and associated clinical outcomes with the WATCHMAN left atrial appendage closure device for embolic protection in patients with atrial fibrillation (from the PROTECT-AF Trial)","volume":"117","author":"Main","year":"2016","journal-title":"Am J Cardiol"},{"issue":"24","key":"10.1016\/j.chest.2018.07.040_bib450","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.jacc.2015.04.025","article-title":"Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis","volume":"65","author":"Holmes","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib451","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9689","key":"10.1016\/j.chest.2018.07.040_bib452","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib453","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/j.hrthm.2015.06.034","article-title":"2015 ACC\/HRS\/SCAI left atrial appendage occlusion device societal overview","volume":"12","author":"Masoudi","year":"2015","journal-title":"Heart Rhythm"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib454","first-page":"700","article-title":"Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience","volume":"77","author":"Park","year":"2011","journal-title":"Catheter Cardiovasc Interv"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib455","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s00392-015-0828-1","article-title":"Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation","volume":"104","author":"Gloekler","year":"2015","journal-title":"Clin Res Cardiol"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib456","article-title":"Comparative effectiveness of interventions for stroke prevention in atrial fibrillation: a network meta-analysis","volume":"5","author":"Tereshchenko","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.chest.2018.07.040_bib457","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jcin.2016.01.038","article-title":"Clinical implications of leaks following left atrial appendage ligation with the LARIAT device","volume":"9","author":"Gianni","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"14","key":"10.1016\/j.chest.2018.07.040_bib458","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.jacc.2018.01.076","article-title":"Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation","volume":"71","author":"Fauchier","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.chest.2018.07.040_bib459","doi-asserted-by":"crossref","unstructured":"Dukkipati SR, Kar S, Holmes DR, Jr., et\u00a0al. Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes [published online ahead of print May 11, 2018]. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.035090.","DOI":"10.1161\/CIRCULATIONAHA.118.035090"},{"issue":"7","key":"10.1016\/j.chest.2018.07.040_bib460","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.hrthm.2015.03.028","article-title":"Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization","volume":"12","author":"Aryana","year":"2015","journal-title":"Heart Rhythm"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib461","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jacc.2008.03.067","article-title":"Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography","volume":"52","author":"Kanderian","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib462","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ahj.2004.09.054","article-title":"Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke","volume":"150","author":"Healey","year":"2005","journal-title":"Am Heart J"},{"issue":"11","key":"10.1016\/j.chest.2018.07.040_bib463","first-page":"1443","article-title":"Left Atrial Appendage Occlusion Study II (LAAOS II)","volume":"29","author":"Whitlock","year":"2013","journal-title":"Can J Cardiol"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib464","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1742-1241.2010.02553.x","article-title":"Peri-operative management of patients taking antithrombotic therapy: need for an integrated proactive approach","volume":"65","author":"Boriani","year":"2011","journal-title":"Int J Clin Pract"},{"issue":"2 Suppl","key":"10.1016\/j.chest.2018.07.040_bib465","doi-asserted-by":"crossref","first-page":"e326S","DOI":"10.1378\/chest.11-2298","article-title":"Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Douketis","year":"2012","journal-title":"Chest"},{"issue":"suppl 5","key":"10.1016\/j.chest.2018.07.040_bib466","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.amjmed.2016.02.001","article-title":"North American Thrombosis Forum, AF Action Initiative Consensus Document","volume":"129","author":"Ruff","year":"2016","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib467","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/europace\/euq109","article-title":"An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality","volume":"12","author":"Aliot","year":"2010","journal-title":"Europace"},{"key":"10.1016\/j.chest.2018.07.040_bib468","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2296-5-15","article-title":"Patients' perspectives on taking warfarin: qualitative study in family practice","volume":"5","author":"Dantas","year":"2004","journal-title":"BMC Family Practice"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib469","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ijcard.2005.07.031","article-title":"Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project","volume":"110","author":"Lane","year":"2006","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.chest.2018.07.040_bib470","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejim.2006.11.005","article-title":"Oral anticoagulation in atrial fibrillation: a pan-European patient survey","volume":"18","author":"Lip","year":"2007","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.chest.2018.07.040_bib471","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/hs0102.101817","article-title":"Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project","volume":"33","author":"Lip","year":"2002","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib472","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.hrtlng.2007.02.006","article-title":"Knowledge and self-management behaviors of patients with recently detected atrial fibrillation","volume":"37","author":"McCabe","year":"2008","journal-title":"Heart Lung"},{"issue":"8","key":"10.1016\/j.chest.2018.07.040_bib473","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.06.026","article-title":"HRS\/NSA 2014 survey of atrial fibrillation and stroke: gaps in knowledge and perspective, opportunities for improvement","volume":"24","author":"Frankel","year":"2015","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib474","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/ageing\/30.6.473","article-title":"Risk communication and older people-understanding of probability and risk information by medical inpatients aged 75 years and older","volume":"30","author":"Fuller","year":"2001","journal-title":"Age Ageing"},{"issue":"6","key":"10.1016\/j.chest.2018.07.040_bib475","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/ageing\/afh202","article-title":"Avoidance hierarchies and preferences for anticoagulation\u2014semi-qualitative analysis of older patients' views about stroke prevention and the use of warfarin","volume":"33","author":"Fuller","year":"2004","journal-title":"Age Ageing"},{"issue":"5","key":"10.1016\/j.chest.2018.07.040_bib476","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2174\/1381612820666140825125715","article-title":"Best practice for atrial fibrillation patient education","volume":"21","author":"Lane","year":"2015","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.chest.2018.07.040_bib477","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2147\/JMDH.S19315","article-title":"What patients want and need to know about atrial fibrillation","volume":"4","author":"McCabe","year":"2011","journal-title":"J\u00a0Multidisciplinary Healthcare"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib478","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40271-016-0180-1","article-title":"Factors Affecting patients' perception on, and adherence to, anticoagulant therapy: anticipating the role of direct oral anticoagulants","volume":"10","author":"Pandya","year":"2017","journal-title":"Patient"},{"issue":"10105","key":"10.1016\/j.chest.2018.07.040_bib479","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(17)31072-3","article-title":"The future of atrial fibrillation management: integrated care and stratified therapy","volume":"390","author":"Kirchhof","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.chest.2018.07.040_bib480","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ijcard.2012.12.047","article-title":"The atrial fibrillation knowledge scale: development, validation and results","volume":"168","author":"Hendriks","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.chest.2018.07.040_bib481","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ijcard.2016.08.303","article-title":"Knowledge gaps in patients with atrial fibrillation revealed by a new validated knowledge questionnaire","volume":"223","author":"Desteghe","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.chest.2018.07.040_bib482","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12959-015-0046-0","article-title":"Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients","volume":"13","author":"Heidbuchel","year":"2015","journal-title":"Thrombosis Journal"},{"key":"10.1016\/j.chest.2018.07.040_bib483","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1471-2261-13-108","article-title":"Patient perspective on the management of atrial fibrillation in five European countries","volume":"13","author":"Bakhai","year":"2013","journal-title":"BMC Cardiovasc Dis"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236921832244X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001236921832244X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:06:41Z","timestamp":1757923601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001236921832244X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":483,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S001236921832244X"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2018.07.040","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic Therapy for Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2018.07.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}